Synergistic Combinations for Enhanced Ocular Delivery of Cell Permeant Therapeutics
Legal Citation
Summary of the Inventive Concept
The inventive concept integrates the patented ocular delivery technology with distinct technologies such as AI, IoT, blockchain, and new materials to create a more powerful system for treating retinal edema.
Background and Problem Solved
The original patent disclosed compositions and methods for the inhibition of diab, but it had limitations in terms of personalized treatment, real-time monitoring, and data management. The new inventive concept addresses these limitations by incorporating AI, IoT, blockchain, and new materials to create a synergistic combination that enhances the ocular delivery of cell permeant therapeutics.
Detailed Description of the Inventive Concept
The inventive concept comprises an ocular delivery device integrated with an AI-powered diagnostic module for detecting retinal edema in a patient. The device is further connected to a blockchain-based data management system that stores patient data and automates treatment protocols through smart contracts. Additionally, the system includes an IoT-enabled ocular delivery device that administers a conjugate comprising an X-linked inhibitor of apoptosis (XIAP)-baculoviral IAP repeat 3 (BIR3) to the patient. The conjugate is formulated with a cell-penetrating peptide and a new material with enhanced biocompatibility and biodegradability.
Novelty and Inventive Step
The new claims introduce the concept of synergistic combinations of distinct technologies to enhance the ocular delivery of cell permeant therapeutics, which is not obvious from the original patent. The integration of AI, IoT, blockchain, and new materials provides a non-obvious solution to the limitations of the original patent.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include the use of different AI algorithms, IoT protocols, or blockchain platforms. Variations could also include the integration of other distinct technologies, such as nanotechnology or gene editing, to further enhance the ocular delivery of cell permeant therapeutics.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the pharmaceutical and biotechnology industries, particularly in the area of retinal disease treatment. The integration of AI, IoT, blockchain, and new materials could provide a competitive advantage in the market and address the growing need for personalized and efficient treatment options.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K38/55 |
| A | A61 | A61K9/0048 |
| A | A61 | A61K47/64 |
| A | A61 | A61P27/02 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical biotechnology with specialization in ocular drug delivery systems, focusing on targeted therapeutic conjugates for retinal treatments, requiring advanced knowledge of peptide chemistry, drug formulation, and medical device integration
Person of Ordinary Skill (PHOSITA) Profile
A biomedical engineer or pharmaceutical scientist with expertise in protein conjugation, cell-penetrating peptide technologies, and advanced drug delivery mechanisms, possessing advanced degrees and 3-5 years of specialized research experience
Obviousness Rationale
A PHOSITA would recognize that integrating emerging digital technologies with established ocular drug delivery mechanisms represents a predictable extension of existing therapeutic approaches. The core therapeutic mechanism of the XIAP-BIR3 conjugate remains consistent, with technological augmentation providing enhanced diagnostic and treatment monitoring capabilities. The fundamental molecular interactions and therapeutic goals remain unchanged, suggesting these variations would be obvious evolutionary developments in the field.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,609 |
|---|---|
| Title | Ocular delivery of cell permeant therapeutics for the treatment of retinal edema |
| Assignee(s) | The Trustees of Columbia University in the City of New York |